0.000369412633912138 -0.00184706316956043 -0.000369412633912006 0.00664942741041743 0.0129294421869228 0.00923531584780199 0.00849649057997785 0.00849649057997785
Sign Up Today X
Thanks for submitting the form.
Stockreport

Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]

NovoCure Limited - Ordinary Shares (NVCR)  More Company Research Source: Seeking Alpha
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
2025 revenue grew 8% to $655 million, but new indications like NSCLC and mesothelioma contributed minimally and face adoption challenges. Gross margins declined to 73–74%, highlighting economic and execution difficulties as NVCR expands beyond its core market. Upcoming 2026 catalysts include PANOVA-4 data, but commercial prospects outside glioblastoma remain highly uncertain amid rising expenses. Mark Kostich/iStock via Getty Images NovoCure Limited ( NVCR ) is a stock that I've covered since 2017. The company markets tumor-treating fields (TTFields) for the treatment of cancer. Over the last few years, in my view, it's become obvious that TTFields don't have much utility This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensati [Read more]
IMPACT SNAPSHOT EVENT TIME: NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
NVCR alerts
from News Quantified
NVCR
NEWS
NVCR
Earnings
NVCR
Analyst Actions
NVCR
SEC Filings
Stockreport

Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]

NovoCure Limited - Ordinary Shares  (NVCR) 
More Company Research Source: Seeking Alpha
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
2025 revenue grew 8% to $655 million, but new indications like NSCLC and mesothelioma contributed minimally and face adoption challenges. Gross margins declined to 73–74%, highlighting economic and execution difficulties as NVCR expands beyond its core market. Upcoming 2026 catalysts include PANOVA-4 data, but commercial prospects outside glioblastoma remain highly uncertain amid rising expenses. Mark Kostich/iStock via Getty Images NovoCure Limited ( NVCR ) is a stock that I've covered since 2017. The company markets tumor-treating fields (TTFields) for the treatment of cancer. Over the last few years, in my view, it's become obvious that TTFields don't have much utility This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensati [Read more]
IMPACT SNAPSHOT
EVENT TIME:
NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS